Get subscribed to our newsletter
Get interesting updates to your email inbox.
Researchers have obtained a highly accurate recreation of human glioblastoma’s features using a novel 3D microscopy analysis.
The study, published in the journal Acta Neuropathologica Communications, provides new information to help with the diagnose, by finding therapeutical targets and designing immunotherapeutic strategies.
This new analysis of 3D images and quantitative data “will help to appreciate from within how the tumor is built in its full dimensionality, and to identify where different cell types are located,” explained researcher George Paul Cribaro from the Universitat AutAnoma de Barcelona.
Please Follow NewsGram on Facebook To Get Latest Updates!
“It provides more complete information than the usual 2D analyses performed for neuropathological diagnosis,” Cribaro added.
With this new approach, the research team showed the alterations in tumour blood vessels, and that these vascular wall abnormalities do not hinder the entrance of lymphocytes T (potential defense against tumoral cells), which is relevant for the design and use of immunotherapies targeting malignant cells.
Moreover, the images allow the tumour to be differentiated into two areas, the tumor tissue properly speaking, and the stroma, which gives support to the tumor, in which there are different immunological microenvironments, the team said.
The work provides a set of resource images that will facilitate the understanding of the complexity of this tumor, showing some aspects to be considered when designing new therapeutic approaches. (IANS)
There are many who certify that Homoeopathy can do wonders in cases of skin related viral diseases, Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) said on Monday.
A case study published recently in AYUHOM, the Research Journal of the North Eastern Institute of Ayurveda and Homoeopathy, Shillong illustrates this point, mentioned AYUSH.
Follow NewsGram on Quora Space to get answers to all your questions.
The case study has been authored by Sangita Saha, Reader, Department of Organon of Medicine and Mahakas Mandal, Post Graduate Trainee, Department of Practice of Medicine, the Calcutta Homeopathic Medical College and Hospital along with Koushik Bhar, Post Graduate Trainee, and the National Institute of Homoeopathy, Kolkata.
Treatment of five patients suffering with five different skin diseases with Homoeopathy has given notable results which give a boost to the conviction of the positive effects of Homoeopathic medicine on such skin disorders.
Skin diseases are numerous and frequently occurring health problems affecting all ages, not only India, but globally also.
The Global Burden of Disease project has shown that the skin diseases continue to be the fourth leading cause of non-fatal disease burden worldwide.
Experts engaged with Homoeopathy treatment opine that Homeopathic approach to common viral skin diseases can be a game changer in offering affordable and effective solutions to a large number of people.
Want to read more in Hindi? Checkout: श्रीकांत दातार बने हार्वर्ड बिजनेस स्कूल के डीन
The case study was done on five patients with Wart, Herpes Zoster and Molluscan Contagiosum. Skin warts are benign tumours caused by infection of keratinocytes. Herpes Zoster results from reactivation of varicella-zoster virus (that also causes chickenpox). On the other hand, Molluscan contagiosum is a viral skin infection caused by closely related types of Pox Virus, and is common with children worldwide, especially in warm climates.
“It is known that Homoeopathy treats the patient, not the disease. Thus, the skin manifestations were treated by the means of internal medication following the principles of Homoeopathy, in these cases. And the results are extremely encouraging,” the Ministry said.
After applying the indicated medicines as per the guidelines of Organon of Medicine and in different phases as per the susceptibility of each individual patient, it has come out that the medicines were able to not only remove the skin lesion efficiently, but also to provide relief to the associated symptoms of the patient.
“Not only that, none of the patients complained about any adverse effect during the treatment.”
The case studies can be considered as a pilot project, said the Ministry, adding randomised controlled trials with larger sample size can be taken up in the next stage so that conclusive evidence on the healing power of Homoeopathy for viral skin diseases can be generated. (IANS)
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer, showed results of a major trial which could change clinical practice.
Final results from the trial showed that olaparib — a pioneering type of drug called a PARP inhibitor, a cancer drug to target an inherited genetic fault — can be used successfully to treat prostate cancers with a weakness in their ability to repair damaged DNA.
The drug was more effective than the modern hormone treatments abiraterone and enzalutamide at slowing down the growth and spread of prostate cancer in patients with advanced disease, the results showed.
Follow NewsGram on LinkedIn to know what’s happening around the world.
The trial had already reported an improvement in disease development and outcome for this group of men with DNA repair faults in their tumours — but the final results published at this stage offer a longer follow-up and conclusively demonstrate an improvement in survival for men who were given olaparib.
The trial studied 387 men with advanced prostate cancer who had defects in one or more of 15 DNA repair genes.
Scientists at The Institute of Cancer Research (ICR), London, were the first to discover how olaparib could be targeted at tumours with faults in their ability to repair DNA.
They now expect the concluding results from the trial — presented at the European Society for Medical Oncology on Sunday and published in the journal The New England Journal of Medicine at the same time — to pave the way for regulatory approval of olaparib in prostate cancer in Europe and in the UK.
“I’m confident that our results will transform prostate cancer treatment – hopefully very soon,” said study co-leader Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London.
Want to read more in Hindi? Checkout: किसे अपना कहें और किसे गैरों का समझें?
“We have shown that olaparib, a drug already approved for use in breast and ovarian cancer, can extend the lives of men with advanced prostate who have defects in the genes BRCA1, BRCA2 or ATM and who have been treated with enzalutamide or abiraterone,”
said de Bono who is also Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.
“The FDA (Food and Drug Administration) has already approved olaparib for prostate cancer in the US and I hope that the final results of our trial will bring the authorisation of this innovative drug to Europe and the UK as soon as possible,” he said.
Men whose tumours had genetic changes were assigned to two groups: one group for those with changes in BRCA1, BRCA2 or ATM, and another group for men with genetic changes in any other of the DNA repair genes studied.
Men were then randomly assigned to olaparib or standard hormone therapy.
DNA damage is the basic cause of cancer — but it is also a key weakness of cancer that can be exploited, since cancer cells need to be able to repair their own DNA too.
In the final analysis of data from the “PROfound” trial, researchers found that olaparib blocked prostate cancer growth more effectively than the modern targeted hormone treatments abiraterone and enzalutamide in men with faulty DNA repair genes.
Patients with genetic alterations in the DNA repair genes BRCA1, BRCA2 or ATM who received olaparib had a median overall survival of 19.1 months, compared with 14.7 months for those on targeted hormone treatments, showed the results. (IANS)